Keyphrases
Celiac Disease
100%
Dermatitis Herpetiformis
38%
Confidence Interval
34%
Disease Phenotype
31%
Ustekinumab
30%
Crohn's Disease
27%
Hazard Ratio
27%
Malignancy
25%
Disease Activity
25%
Drug Persistence
25%
Cause of Death
25%
Biological Therapy
25%
Long-term Cohort Study
25%
Vascular Disease
25%
Disease Groups
25%
Renal Comorbidities
25%
Dual Biological Therapy
25%
Inflammatory Bowel Disease
25%
Cancer Incidence
25%
Standardized Incidence Ratio
17%
Kidney Disease
12%
Tampere
11%
University Hospital
11%
Risk of Malignancy
10%
Non-Hodgkin Lymphoma
10%
Treatment Persistence
8%
Overall Risk
7%
Malabsorption
7%
Screen-detected
7%
Disease Diagnosis
6%
Medical Records
6%
Catchment Area
6%
Disease Pattern
6%
Villous Atrophy
6%
Long-term Mortality
6%
Refractory Inflammatory Bowel Disease
5%
Adalimumab
5%
Remission
5%
Glomerulonephritis
5%
IgA Nephropathy (IgAN)
5%
Pharmacology, Toxicology and Pharmaceutical Science
Coeliac Disease
75%
Ustekinumab
41%
Crohn's Disease
33%
Disease Activity
25%
Cancer Incidence
25%
Inflammatory Bowel Disease
25%
Comorbidity
25%
Biological Product
20%
Remission
16%
Adalimumab
16%
Standardized Incidence Ratio
15%
Dermatitis Herpetiformis
13%
Kidney Disease
12%
Diseases
9%
Nonhodgkin Lymphoma
9%
Biological Marker
8%
Infection Complication
8%
Cohort Study
6%
Intestine Villus Atrophy
6%
Malabsorption
6%
Glomerulonephritis
5%
Immunoglobulin A Nephropathy
5%
Medicine and Dentistry
Coeliac Disease
75%
Dermatitis Herpetiformis
38%
Cohort Analysis
28%
Cancer Incidence
25%
Vascular Disease
25%
Cancer
25%
Comorbidity
25%
Standardized Incidence Ratio
15%
Hazard Ratio
15%
Non-Hodgkin Lymphoma
9%
Kidney Disorder
7%
Malabsorption
6%
Cerebrovascular Disease
6%
Diagnosis
5%
Nephropathy
5%
Immunoglobulin A Nephropathy
5%
Glomerulonephritis
5%
